DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy

Information source: Seoul National University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoarthritis, Knee

Intervention: Allogenic bone graft (Procedure); Synthetic bone substitute (geneX®) (Procedure)

Phase: Phase 4

Status: Recruiting

Sponsored by: Seoul National University Hospital

Official(s) and/or principal investigator(s):
Tae Kyun Kim, MD, PhD, Principal Investigator, Affiliation: Joint Reconstruction Center, Seoul National University Bundang Hospital

Overall contact:
Tae Kyun Kim, MD, PhD, Phone: 82-31-787-7196, Email: osktk@snubh.org

Summary

This study is conducted to determine whether a new synthetic bone substitute is better than allogenic bone graft for addressing bone defect in medial open wedge high tibial osteotomy in terms of postoperative pain, postoperative bleeding, operation time and bone healing. The investigators hypothesized the new synthetic bone substitute would bring better outcomes in the outcome variables mentioned above.

Clinical Details

Official title: Outcome Comparison of Allogenic Cancellous Bone and a New Synthetic Bone Substitute (geneX«) in Filling the Bone Defect Created With Medial Open Wedge High Tibial Osteotomy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Temporal change of postoperative pain

Secondary outcome:

Pre&postoperative Hemoglobin level

Total operation time

Temporal change of weight bearing status

Temporal change of pain with weight bearing

Amount of drainage

Working time for bone defect filling

Temporal progression of bone healing on X-rays

Detailed description: High tibial osteotomy is a well-established treatment option for the young patients (aged 40~55years) with knee osteoarthritis which is confined in medial compartment of the knee. Classical technique was lateral closing wedge osteotomy, but recently medial open wedge osteotomy has gained popularity with the advent of new fixation devices and refined surgical techniques. The surgeon can correct the deformity more precisely in both coronal and sagittal planes simultaneously with medial opening technique. And it can avoid complications associated with lateral closing technique like tibial shaft offset or peroneal nerve palsy. But medial opening technique inevitably creates large bone defect, which has to be addressed to avoid complications like loss of correction or delayed/non-union. Autologous bone is widely accepted as a standard for filling bone defects, but its supply is limited and harvesting autologous bone adds to surgical morbidity like bleeding, pain or fracture at the donor site. Therefore, there has been much effort to find materials to substitute autologous bone. Many studies reported the results of using allogenic bone for addressing bone defects and most of them showed favorable results. But some allogenic bone products are cumbersome to process to make it fit to the defect, and there are potential risk of disease transmission, if the products are not properly treated. Bone cements of several different composition has been developed and when used for filling bone defect, they also showed good results in general. Recently, a new synthetic bone substitute based on calcium phosphate and calcium sulfate (geneX®, Biocomposites Co.,Ltd.) has been introduced and is commercially available. While providing initial mechanical strength, its calcium sulfate component is rapidly absorbed to provide space for new bone ingrowth and its surface is made to negatively charged, which helps accelerate new bone formation. It is provided as an injectable paste, which is easier to handle than allogenic bone, so it may help reduce operation time. With these theoretical advantages, there are some anecdotal reports that patients treated with geneX® presented less postoperative pain and bleeding than patients treated with allogenic bone graft. Therefore, we conducted this study to determine whether the new synthetic bone substitute (geneX®) is better than allogenic bone for addressing bone defect created in medial open wedge high tibial osteotomy.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of primary osteoarthritis of the knee which is confined to medial

compartment

- Scheduled for high tibial osteotomy

- Written signed consent available

Exclusion Criteria:

- Patients who refuse to participate in the study

- Previous history of major orthopedic surgery around the operating knee

- Congenital anomaly involving proximal tibia

- Revision high tibial osteotomy

- Patients who is receiving another major knee surgery simultaneously with high tibial

osteotomy at the same knee

Locations and Contacts

Tae Kyun Kim, MD, PhD, Phone: 82-31-787-7196, Email: osktk@snubh.org

Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-Si, Gyeonggi-do 463-707, Korea, Republic of; Recruiting
Tae Kyun Kim, MD, PhD, Phone: 82-31-787-7196, Email: osktk@snubh.org
Additional Information

Starting date: October 2013
Last updated: October 13, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017